

**For Immediate Release
Alembic Pharmaceuticals Ltd.
Consolidated Audited Results for quarter / year ended
31.03.2012**

Editors Synopsis

Quarter ended 31st March 2012

- For the quarter net sales up 15% at Rs 342.30 crores against Rs. 297.73 crores in corresponding quarter last year
- Domestic formulations up 17% at Rs. 184.47 crores against Rs. 157.41 crores in corresponding quarter last year
- Profit before tax up by 107% at Rs. 26.94 crores against Rs. 13.03 crores in corresponding quarter in last year
- Net Profit after tax up by 98% at Rs. 20.31 crores against Rs. 10.28 crores in corresponding quarter in last year
- 4 ANDA filed during the quarter. 2 ANDA approvals received in current quarter. 3 DMF's filed during the quarter

Year ended 31st March 2012

- Net sales grew by 22% for full year at Rs. 1467.89 crores against Rs. 1206.64 crores - Domestic by 11% and Exports by 41%
- Profit before tax up by 51% at Rs. 160.99 crores against Rs. 106.85 crores in last year
- Profit after tax up by 52% at Rs. 130.14 crores against Rs. 85.39 crores in last year
- EBIDTA margins 15% at Rs. 220.41 crores against 13% at Rs. 160.25 crores in last year
- 45 Cumulative ANDA filings, 19 approvals in place. Cumulative DMF filings at 62.

Vadodara, 25th April 2012

Alembic Pharmaceuticals Limited, the pharmaceutical major, today reported a 15% increase in revenues to Rs 342.30 crores for the quarter ended 31st March 2012, compared to Rs 297.73 crores in the corresponding quarter last year.

The Company posted an impressive 107% growth in profit before tax at Rs. 26.94 crores for the quarter ended March 2012 against Rs 13.03 crores posted in corresponding quarter last fiscal.

For full year 2011-12, company posted robust 51% growth in profit before tax of Rs. 160.99 crores against Rs. 106.85 crores for previous year.

The net profit grew by 98% at Rs. 20.31 crores for the quarter ended March 2012 against Rs. 10.28 crores in corresponding quarter last fiscal.

The net profit for year 11-12 grew by 52% at Rs. 130.14 crores against Rs. 85.39 crores in corresponding quarter last fiscal.

Domestic Formulation Business

The domestic formulations posted sales of Rs. 184.47 crores against Rs. 157.41 crores registering healthy 17% growth over the corresponding quarter of the previous year.

Full year numbers were also encouraging since company posted 13% growth in sales at Rs. 782.61 crores against Rs. 693.44 crores in previous year.

Alembic has maintained market share of 1.75%.

Alembic has four brands in the list of top 300 brands of the industry i.e. 'Azithral' , 'Roxid', 'Althrocin' and 'Wikoryl'.

API

For the quarter, Export API recorded sales of Rs. 68.14 crores against Rs. 34.20 crores registering growth of 99% while Domestic API sales recorded sales of Rs. 19.21 crores against Rs. 32.13 crores of PY.

On full year basis, Export API grew by 55% to Rs. 279.22 crores against Rs. 179.90 crores last year. Domestic API recorded sales of Rs. 94.24 crores against Rs. 94.51 crores in previous year.

International Generics

International generics clocked sales of Rs. 50.37 crores against Rs. 55.29 crores over corresponding quarter last year. On full year basis sales grew by robust 39% to Rs. 241.80 crores from Rs. 173.77 crores.

Cumulative ANDA filings at 45. Cumulative ANDA approvals now stands at 19. Cumulative DMF filings at 62.

Summary of total revenue (consolidated) for the quarter is as under:

(Rs. in Lacs)

Particulars			
	Q4FY12	Q4FY11	% Change
Formulation			
Domestic	18447	15741	17%
International Branded	1774	1370	29%
International Generics	5037	5529	(-)9%
API			
Domestic	1921	3213	(-)40%
International	6814	3420	99%
Export Incentives	237	500	(-)53%
Total	34,230	29,773	15%

Summary of total revenue (consolidated) for the full year is as under:

(Rs. in Lacs)

Particulars			
	FY 11-12	FY 10-11	% Change
Formulation			
Domestic	78,261	69,344	13%
International Branded	5,670	5,015	13%
International Generics	24,180	17,377	39%
API			
Domestic	9,424	9,451	- %
International	27,922	17,990	55%
Export Incentives	1,332	1,487	(-)10%
Total	146,789	120,664	22%

The Profit break-up for the quarter:

(Rs. in Lacs)

Particulars	Q4FY12	Q4FY11	% Growth
Operating Income	4125	2723	51%
Profit Before Tax	2694	1303	107%
Net Profit after Tax	2031	1028	98%

The Profit break-up for the full year:

(Rs. in Lacs)

Particulars	FY 11-12	FY 10-11	% Growth
Operating Income	22041	16025	38%
Profit Before Tax	16099	10685	51%
Net Profit after Tax	13014	8539	52%

Dividend

The Board has recommended dividend on equity shares at Rs. 1.40 per share i.e. 70% for 11-12 (P.Y. Re. 1 per share i.e. 50%)

Capital Expenditure

The company has set up a state of art 90 bedded bio equivalence centre capable of carrying out 100 pilot / pivotal studies every year.

The Company is in midst of significant expansion of its regulated formulation manufacturing plant which will enhance capacity from existing 2.6 bn tablets / capsules to 5.0 bn per annum.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in Macrolides segment of anti-infective drugs in India.

Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and semi-regulated export market. The company has a state of the art Research Centre at Vadodara.

For more information:

Mitanshu Shah

Phone: +91 265 – 3007630

Email: mitanshu.shah@alembic.co.in

Alembic Pharmaceuticals Limited